| Product NDC: | 0056-0654 |
| Proprietary Name: | SINEMET |
| Non Proprietary Name: | CARBIDOPA AND LEVODOPA |
| Active Ingredient(s): | 25; 250 mg/1; mg/1 & nbsp; CARBIDOPA AND LEVODOPA |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0056-0654 |
| Labeler Name: | Bristol-Myers Squibb Pharma Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA017555 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20090601 |
| Package NDC: | 0056-0654-68 |
| Package Description: | 100 TABLET in 1 BOTTLE (0056-0654-68) |
| NDC Code | 0056-0654-68 |
| Proprietary Name | SINEMET |
| Package Description | 100 TABLET in 1 BOTTLE (0056-0654-68) |
| Product NDC | 0056-0654 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CARBIDOPA AND LEVODOPA |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20090601 |
| Marketing Category Name | NDA |
| Labeler Name | Bristol-Myers Squibb Pharma Company |
| Substance Name | CARBIDOPA; LEVODOPA |
| Strength Number | 25; 250 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA],Aromatic Amino Acid Decarboxylation Inhibitor [EPC],DOPA Decarboxylase Inhibitors [MoA] |